Biodesix closes on $5.2 million, plans to raise another $5 million

BOULDER — Biodesix Inc., a life-sciences company that does molecular diagnostics tests, has closed on $5.28 million in capital.

The company raised the funds through convertible promissory notes and equity securities issuable upon the conversion of the notes, according to a Form D filed with the U.S. Securities and Exchange Commission on May 8.

CEO David Brunel told BizWest that the company plans to close on another $5 million in funding in the next few weeks.

Biodesix, which makes blood-based molecular tests, is raising the capital because of its continuing growth, Brunel said.



Leave a Reply

Your email address will not be published.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>